Oxford Biomedica plc (LON:OXB - Get Free Report) shares hit a new 52-week high during trading on Thursday . The stock traded as high as GBX 580 ($7.86) and last traded at GBX 580 ($7.86), with a volume of 77568 shares traded. The stock had previously closed at GBX 575 ($7.79).
Analysts Set New Price Targets
Several equities analysts have recently issued reports on OXB shares. Peel Hunt reaffirmed a "buy" rating and set a GBX 451 price target on shares of Oxford Biomedica in a research note on Friday, August 1st. JPMorgan Chase & Co. lowered their target price on shares of Oxford Biomedica from GBX 490 to GBX 400 and set a "neutral" rating for the company in a research note on Tuesday, July 15th. Finally, Royal Bank Of Canada lifted their target price on shares of Oxford Biomedica from GBX 800 to GBX 930 and gave the stock an "outperform" rating in a research note on Tuesday, August 26th. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Oxford Biomedica has a consensus rating of "Moderate Buy" and a consensus target price of GBX 540.25.
Read Our Latest Research Report on Oxford Biomedica
Oxford Biomedica Stock Up 0.2%
The stock's fifty day moving average is GBX 446.32 and its two-hundred day moving average is GBX 352.72. The company has a current ratio of 2.35, a quick ratio of 1.67 and a debt-to-equity ratio of 166.48. The firm has a market cap of £710.79 million, a P/E ratio of -1,416.61 and a beta of 1.09.
Insider Buying and Selling
In other news, insider Roch Doliveux bought 67,000 shares of the firm's stock in a transaction that occurred on Friday, August 15th. The shares were acquired at an average price of GBX 450 per share, with a total value of £301,500. Also, insider Heather Preston purchased 11,389 shares of the firm's stock in a transaction dated Tuesday, June 17th. The stock was bought at an average cost of GBX 324 per share, for a total transaction of £36,900.36. 43.30% of the stock is currently owned by insiders.
Oxford Biomedica Company Profile
(
Get Free Report)
Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
Featured Stories
Before you consider Oxford Biomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.
While Oxford Biomedica currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
